CC, the fourth most frequently diagnosed malignancy in women worldwide, is a major global health challenge, particularly in low-resource regions. Approximately 88.1% of the 604,000 CC new cases occurred in low- and middle-income countries in 2020, and more than 90% of the 342,000 CC deaths occurred in low- and middle-income countries in 2020
1. China, as one of the most populous developing countries worldwide, accounts for 18% of global CC incidence and 17% of global CC deaths
1. In 2016, 119,300 CC new cases and 37,200 deaths occurred in China
2. Although CC incidence and mortality in China were lower than the global average level, the mortality was 2 times higher than that in the USA and UK
3. Overall, the incidence and mortality rates of CC in China are increasing, particularly in rural areas (annual percentage change in incidence during 2007–2014 of 6.0 and 2.2 in rural and urban areas, respectively)
4,5. Gaps in CC prevention between China and the developed world, as well as among regions of China, highlight the necessity for implementing comprehensive and sustainable CC control strategies tailored to the socioeconomic development of different areas of China.